Spero Therapeutics (NASDAQ:SPRO – Get Rating) announced its quarterly earnings data on Monday. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.14), MarketWatch Earnings reports. Spero Therapeutics had a negative net margin of 491.65% and a negative return on equity of 87.72%. During the same period in the […]
Spero Therapeutics (NASDAQ:SPRO – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. […]
Spero Therapeutics (NASDAQ:SPRO – Get Rating) will post its quarterly earnings results after the market closes on Thursday, March 31st. Analysts expect Spero Therapeutics to post earnings of ($0.81) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link. Shares of Spero Therapeutics stock […]
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September.